Veracyte CCO sells 4,015 shares at $40 each

Veracyte’s Global Chief Commercial Officer sold 4,015 shares under a Rule 10b5-1 trading plan and continues to hold 124,329 shares.

Rhea-AI Filing Summary

VERACYTE, INC. (VCYT) reported that Global Chief Commercial Officer John Leite sold 4,015 shares of common stock on September 21, 2026 at $40.00 per share in an open-market or private transaction. After this sale, he directly holds 124,329 shares of Veracyte common stock. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Leite on June 9, 2026.

Insider Trade Summary 10b5-1

Net Seller: 4,015 shares

Net Sell 1 txn

Insider Leite John

Role Global Chief Commercial Off

Sold 4,015 shs ($161K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	4,015	$40.00	$161K

Holdings After Transaction: Common Stock — 124,329 shares (Direct)

Footnotes (1)

1. F1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2026.

Key Figures

Shares sold: 4,015 shares Sale price per share: $40.00 per share Shares owned after transaction: 124,329 shares +2 more

5 metrics

Shares sold 4,015 shares Common stock sold by John Leite on September 21, 2026

Sale price per share $40.00 per share Price received in the September 21, 2026 sale

Shares owned after transaction 124,329 shares Direct holdings of John Leite following the reported sale

Net shares sold 4,015 shares Net change in John Leite’s holdings from this Form 4

Rule 10b5-1 plan adoption date June 9, 2026 Date Leite adopted the trading plan covering these transactions

Key Terms

Rule 10b5-1 plan, open market, Common Stock

3 terms

Rule 10b5-1 plan regulatory

"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market market

"Sale in open market or private transaction"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

Common Stock financial

"Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veracyte (VCYT) disclose for John Leite?

Veracyte disclosed that Global Chief Commercial Officer John Leite sold 4,015 shares of common stock on September 21, 2026, at a price of $40.00 per share, in an open-market or private transaction.

How many Veracyte (VCYT) shares does John Leite hold after this Form 4 sale?

After the reported sale, John Leite directly holds 124,329 shares of Veracyte common stock. This figure reflects his direct ownership position immediately following the September 21, 2026 transaction reported on the Form 4.

Was the Veracyte (VCYT) insider sale by John Leite under a Rule 10b5-1 plan?

Yes. The footnote states that the transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by John Leite on June 9, 2026, indicating they were pre-arranged under that trading plan.

What price did John Leite receive per share in the Veracyte (VCYT) sale?

The sale was reported at a price of $40.00 per share for Veracyte common stock on September 21, 2026, described as an open-market or private transaction.

How large was John Leite’s Veracyte (VCYT) sale in share terms?

John Leite sold 4,015 shares of Veracyte common stock in this reported transaction. This is the only transaction listed on the Form 4 and represents a net disposition of the same number of shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 05:16 PM Accepted by SEC EDGAR 09/22/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leite John

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global Chief Commercial Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		S(1)		4,015	D	$40	124,329	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2026.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)